T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group

Martin, Eléonora De; Senzolo, Marco; Ponziani, Francesca Romana; Paolo, D. Di; Viganò, R.; Marino, M.; Donato, Maria Francesca; Rendina, M.; Morelli, Maria Cristina; Fornasiero, E.; Miglioresi, L.; Giannelli, V.; Fagiuoli, S.; Burra, P.

doi:10.1016/s1590-8658(11)60080-7

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The worse outcomes of HCV‐infected women after transplantation were confirmed in a multicenter, retrospective Italian study . All patients underwent combined antiviral therapy, and fibrosis progression on liver biopsy samples taken before and after antiviral therapy and 1, 3, and 5 years later was evaluated according to the Ishak score.…”

Section: Disease Recurrence After Liver Transplantation From An Age Amentioning

confidence: 96%

“…77 The worse outcomes of HCV-infected women after transplantation were confirmed in a multicenter, retrospective Italian study. 120 All patients underwent combined antiviral therapy, and fibrosis progression on liver biopsy samples taken before and after antiviral therapy and 1, 3, and 5 years later was evaluated according to the Ishak score. Female recipients had a higher risk of fibrosis progression than men after antiviral therapy in a univariate analysis, and this tendency was confirmed at 3 years in both univariate and multivariate analyses.…”

Section: Disease Recurrence After Liver Transplantation From An Age Amentioning

confidence: 99%

See 1 more Smart Citation

Influence of Age and Gender Before and After Liver Transplantation

et al. 2013

View full text Add to dashboard Cite

Women constitute a particular group among patients with chronic liver disease and in the post-liver transplantation (LT) setting: they are set apart not only by traditional differences with respect to men (ie, body mass index, different etiologies of liver disease, and accessibility to transplantation) but also by factors related to hormonal changes that characterize first the fertile age and subsequently the postmenopausal period (eg, disease course variability and responses to therapy). The aim of this review is, therefore, to evaluate the role of the interplay of factors such as age, gender, and hormones in influencing the natural history of chronic liver disease before and after LT and their importance in determining outcomes after LT. As the population requiring LT ages and the mean age at transplantation increases, older females are being considered for transplantation. Older patients are at greater risk for nonalcoholic steatohepatitis, osteoporosis, and a worse response to antiviral therapy. Female gender per se is associated with a greater risk for osteoporosis because of metabolic changes after menopause, the bodily structure of females, and, in the population of patients with chronic liver disease, the prevalence of cholestatic and autoimmune liver diseases. With menopause, the fall of protective estrogen levels can lead to increased fibrosis progression, and this represents a negative turning point for women with chronic liver disease and especially for patients with hepatitis C. Therefore, the notion of gender as a binary female/male factor is now giving way to the awareness of more complex disease processes within the female gender that follow hormonal, social, and age patterns and need to be addressed directly and specifically. Liver Transpl 19:122-134, 2013. V C 2012 AASLD.Received July 24, 2012; accepted November 8, 2012.Gender has scarcely been taken into account when indications, risk factors, and outcomes for liver transplantation (LT) have been evaluated. When gender has been considered, it has always been investigated as a binary male/female combination, and there has been a complete disregard of the fact that for females (and, to a lesser extent, for males), there is a profound difference between reproductive age and menopausal age. The onset of menopause represents a negative turning point for women with chronic liver disease in general and more so for those with a hepatitis C virus (HCV) infection. The aim of this review is, therefore, to evaluate the interplay of factors such as age, gender, and hormones in the natural history of chronic liver disease before and after LT and their importance in determining outcomes.

show abstract

Section: Disease Recurrence After Liver Transplantation From An Age Amentioning

confidence: 96%

Section: Disease Recurrence After Liver Transplantation From An Age Amentioning

confidence: 99%

Influence of Age and Gender Before and After Liver Transplantation

et al. 2013

View full text Add to dashboard Cite

show abstract

“…With combination therapy, the risk is below 10%, and controlled studies have revealed no differences in acute rejection rates between treated patients and untreated controls. A country-based experience [125] reported the results obtained after treatment with standard AT after LT. From this Italian database, patients in whom liver biopsy was performed at least once before and once after completion of therapy were selected for analysis. Both per-protocol biopsies (from the majority of participating centers) and nonprotocol biopsies were included in the study.…”

Section: Antiviral Therapy For Hcv Recurrence: the Pastmentioning

confidence: 99%

“…A country‐based experience reported the results obtained after treatment with standard AT after LT. From this Italian database, patients in whom liver biopsy was performed at least once before and once after completion of therapy were selected for analysis. Both per‐protocol biopsies (from the majority of participating centers) and nonprotocol biopsies were included in the study.…”

Section: Antiviral Therapy For Hcv Recurrence: the Pastmentioning

confidence: 99%

Hepatitis C virus and liver transplantation: where do we stand?

et al. 2015

View full text Add to dashboard Cite

SummaryThe hepatitis C virus (HCV) infects more than 180 million people globally, with increasing incidence, especially in developing countries. HCV infection frequently progresses to liver cirrhosis leading to liver transplantation or death, and HCV recurrence still constitutes a major challenge for the transplant team. Antiviral therapy is the only available instrument to slow down this process, although its actual impact on liver histology, in responders and nonresponders, is still controversial. We are now facing a "new era" of direct antiviral agents that is already changing the approach to HCV burden both in the pre-and in the post-liver transplantation settings. Available data on sofosbuvir/ledipasvir and sofosbuvir/ simeprevir in patients with decompensated cirrhosis sustain a SVR12 of 89% [1], but one-third of patients do not clinically improved. The sofosbuvir/ribavirin treatment in stable cirrhotic patients with HCC before liver transplantation is associated with 2% recurrence rate if liver transplantation is performed at least one month after undetectable HCV-RNA is achieved. The treatment of recurrence with the new antiviral drugs is associated with a SVR that ranges between 60 and 90%. In this review, we have focused on the evolution of antiviral therapy for HCV recurrence from the "old" interferon-based therapy to the "new" interferon-free regimens, highlighting useful information to aid the transplant hepatologist in the clinical practice.

show abstract

T-44 Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group

Cited by 2 publications

References 0 publications

Influence of Age and Gender Before and After Liver Transplantation

Influence of Age and Gender Before and After Liver Transplantation

Hepatitis C virus and liver transplantation: where do we stand?

Contact Info

Product

Resources

About